Sandoz partners with Samsung Bioepis to license Stelara biosimilar
The agreement allows Sandoz exclusive marketing rights for the inflammatory bowel disease therapy in Europe and North America.
The agreement allows Sandoz exclusive marketing rights for the inflammatory bowel disease therapy in Europe and North America.
What's Your Reaction?
